TNGX (Tango Therapeutics) Float Percentage Of Total Shares Outstanding : 82.91% (As of Jul. 13, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tango Therapeutics's float shares is 89.87 Mil. Tango Therapeutics's total shares outstanding is 108.39 Mil. Tango Therapeutics's float percentage of total shares outstanding is 82.91%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tango Therapeutics's Insider Ownership is 2.10%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tango Therapeutics's Institutional Ownership is 104.28%.

Tango Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Tango Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	89.87	/	108.39
	=	82.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tango Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215

Website

https://www.tangotx.com

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Executives

Douglas Barry	officer: See Remarks	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Adam Crystal	officer: See Remarks	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Barbara Weber	director, officer: Chief Executive Officer	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Daniella Beckman	officer: Chief Financial Officer	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Mace Rothenberg	director	171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Lesley Ann Calhoun	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
John B Ketchum	director	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc	director	201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p.	director	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p.	director	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116